{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:12:33Z","timestamp":1790190753525,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jocn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.jocn.2019.08.113","type":"journal-article","created":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T11:06:55Z","timestamp":1567595215000},"page":"316-321","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Efficacy and tolerability of subcutaneously administered immunoglobulin in myasthenia gravis: A systematic review"],"prefix":"10.1016","volume":"72","author":[{"given":"Karen Joy B.","family":"Adiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian I.","family":"Espiritu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir Lennin A.","family":"Roque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Paciano Baltazar T.","family":"Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jocn.2019.08.113_b0005","doi-asserted-by":"crossref","first-page":"s217","DOI":"10.1007\/s10072-003-0081-7","article-title":"Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases","volume":"24","author":"Bayry","year":"2003","journal-title":"Neurol Sci"},{"key":"10.1016\/j.jocn.2019.08.113_b0010","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1212\/WNL.0000000000004365","article-title":"Subcutaneous immunoglobulin in myasthenia gravis exacerbation","volume":"89","author":"Beecher","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2019.08.113_b0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0159993","article-title":"Subcutaneous immunoglobulin therapy in the chronic management of myasthenia gravis: a retrospective cohort study","volume":"11","author":"Bourque","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jocn.2019.08.113_b0020","doi-asserted-by":"crossref","unstructured":"Carr AS, Cardwell CR, Mccarron PO, Mcconville J, 2010. A systematic review of population based epidemiological studies in Myasthenia Gravis.","DOI":"10.1186\/1471-2377-10-46"},{"key":"10.1016\/j.jocn.2019.08.113_b0025","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1023\/A:1006678312925","article-title":"The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy","volume":"20","author":"Chapel","year":"2000","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jocn.2019.08.113_b0030","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3988\/jcn.2018.14.1.98","article-title":"Subcutaneous immunoglobulins are a valuable treatment option in myasthenia gravis","volume":"14","author":"Garnero","year":"2017","journal-title":"J Clin Neurol"},{"key":"10.1016\/j.jocn.2019.08.113_b0035","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01299","article-title":"Adverse effects of immunoglobulin therapy","volume":"9","author":"Guo","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jocn.2019.08.113_b0040","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2019.08.113_b0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/874680","article-title":"Myasthenia gravis: a review","volume":"2012","author":"Jayam Trouth","year":"2012","journal-title":"Autoimmune Dis"},{"key":"10.1016\/j.jocn.2019.08.113_b0050","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1177\/1756285617722437","article-title":"Long-term treatment of refractory myasthenia gravis with subcutaneous immunoglobulin","volume":"10","author":"Kov\u00e1cs","year":"2017","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.jocn.2019.08.113_b0055","doi-asserted-by":"crossref","first-page":"405","DOI":"10.4103\/0028-3886.181542","article-title":"MG-QoL-15 scores in treated myasthenia gravis: experience from a university hospital in India","volume":"64","author":"Kumar","year":"2016","journal-title":"Neurol India"},{"key":"10.1016\/j.jocn.2019.08.113_b0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.jocn.2019.08.113_b0065","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1001\/jamaneurol.2014.17","article-title":"Comparison of plasmapheresis and intravenous immunoglobulin as maintenance therapies for juvenile myasthenia gravis","volume":"71","author":"Liew","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.jocn.2019.08.113_b0070","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/ene.13218","article-title":"Subcutaneous immunoglobulin as first-line therapy in treatment-naive patients with chronic inflammatory demyelinating polyneuropathy: randomized controlled trial study","volume":"24","author":"Markvardsen","year":"2017","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.jocn.2019.08.113_b0075","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/BF00441919","article-title":"Clinical trials of sulfonated immunoglobulin preparation for intravenous administration. II. Adverse reactions","volume":"136","author":"Matsumoto","year":"1981","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.jocn.2019.08.113_b0080","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1002\/mus.21016","article-title":"Disease-specific measure of quality of life for myasthenia gravis","volume":"38","author":"Mullins","year":"2008","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jocn.2019.08.113_b0085","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/CND.0000000000000156","article-title":"Outcome measures in myasthenia gravis","volume":"18","author":"Muppidi","year":"2017","journal-title":"J Clin Neuromuscul Dis"},{"key":"10.1016\/j.jocn.2019.08.113_b0090","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/mus.25409","article-title":"Subcutaneous versus intravenous immunoglobulin for chronic autoimmune neuropathies: a meta-analysis","volume":"55","author":"Racosta","year":"2017","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jocn.2019.08.113_b0095","doi-asserted-by":"crossref","first-page":"346","DOI":"10.2340\/00015555-1471","article-title":"Analysis of high-dose intravenous immunoglobulin therapy in 16 patients with refractory autoimmune blistering skin disease: high efficacy and no serious adverse events","volume":"93","author":"Seidling","year":"2013","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jocn.2019.08.113_b0100","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.tmrv.2013.05.004","article-title":"Adverse effects of human immunoglobulin therapy","volume":"27","author":"Stiehm","year":"2013","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.jocn.2019.08.113_b0105","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.jocn.2019.08.113_b0110","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0953-4431(95)00101-8","article-title":"Myasthenia gravis: pathophysiology, diagnosis, differential diagnosis and management","volume":"7","author":"Thomann","year":"1995","journal-title":"Clin Eye Vis Care"},{"key":"10.1016\/j.jocn.2019.08.113_b0115","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S1474-4422(18)30106-6","article-title":"Intravenous versus subcutaneous immunoglobulin","volume":"17","author":"Uniyal","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jocn.2019.08.113_b0120","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1474-4422(17)30378-2","article-title":"Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"17","author":"van Schaik","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jocn.2019.08.113_b0125","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1177\/1756285615584739","article-title":"Subcutaneous immunoglobulin in treating inflammatory neuromuscular disorders","volume":"8","author":"Yoon","year":"2015","journal-title":"Ther Adv Neurol Disord"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586819315048?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586819315048?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T21:20:24Z","timestamp":1760822424000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586819315048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":25,"alternative-id":["S0967586819315048"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2019.08.113","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and tolerability of subcutaneously administered immunoglobulin in myasthenia gravis: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2019.08.113","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}